Rapport Therapeutics, Inc. · Brief

Next report

130 days

Mar 10 · before openest.Q4 FY26

Expected move

No implied move.

8 reportsHistory

0 of 7≥ implied

Nov 7 '24—▲+2.87%—

Mar 11 '25±41.6%▲+8.34%×0.20

May 8 '25±33.1%▲+4.21%×0.13

Aug 7 '25±34.6%▲+5.48%×0.16

Nov 6 '25±14.5%▼−3.10%×0.21

Q1 FY26±18.4%▼−2.98%×0.16

May 7 '26±13.1%▲+7.74%×0.59

Q2 FY26±14.1%▲+0.57%×0.04

quarterimplied−45%0+45%realized×

Q2 FY26±14.1%▲+0.57%×0.04

May '26±13.1%▲+7.74%×0.59

Q1 FY26±18.4%▼−2.98%×0.16

Nov '25±14.5%▼−3.10%×0.21

Aug '25±34.6%▲+5.48%×0.16

May '25±33.1%▲+4.21%×0.13

2 older reports

Mar '25±41.6%▲+8.34%×0.20

Nov '24—▲+2.87%—

Shaded = implied · tick ▲▼ = realized · × = |realized| ÷ impliedSource: options EOD · implied at prior close · realized close to close

Mar 10 report · est.

—

RAPP report session

No linked exposure.

Oct 30impliedImplied move: ±15.2% into Oct 30 earnings (Oct 30 close).Source

Oct 308-KMaterial agreement: underwriting agreement with Morgan Stanley & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C. as…Source

Oct 22impliedImplied move: ±15.6% into Nov 5 earnings (Oct 22 close).Source

privateThesis 0 · Decisions 0 · Observations 0

No thesis.